A comprehensive overview and safety evaluation of fremanezumab as a preventive therapy for migraine.

A comprehensive overview and safety evaluation of fremanezumab as a preventive therapy for migraine.
Expert Opin Drug Saf. 2020 Mar 02;:
Authors: Parikh SK, Burkett JG, Silberstein SD
Abstract
Introduction: Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP mAb), is a migraine-specific treatment for migraine prevention.Areas covered: This review will briefly discuss other available and emerging CGRP mAbs and the neurophysiology of fremanezumab. The review will focus on phase III trials of the efficacy of fremanezumab for episodic and chronic trials, and a recent pooled safety and tolerability analysis of its use.Expert opinion: Continued efficacy and safety data collection will help guide long-term risk and efficacy counseling in the general population.
PMID: 32116061 [PubMed - as supplied by publisher]

Source: Expert Opinion on Drug Safety - March 3, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research